( ) -q-26- UNDATED (Correspondent Jeremy House) “rare disease treatments.” Federal regulators are suing to block biotech drug developer Amgen’s more than $26 billion deal for Horizon Therapeutics. [CutID: <Cuts> FTC-AMGEN-house-q-WEDam.mp3 Time: 26s Title: FTC-AMGEN-house-q-WEDam Out-cue: rare disease treatments] TAG: Correspondent Jeremy House reporting. ——————————- VERBATIM: The Federal Trade Commission says the deal, announced last […]
Audio
Monopoly concerns push FTC to sue to block Amgen’s more than $26B deal for Horizon
( ) -q-26- UNDATED (Correspondent Jeremy House) “rare disease treatments.”
Federal regulators are suing to block biotech drug developer Amgen’s more than $26 billion deal for Horizon Therapeutics.
[CutID: <Cuts> FTC-AMGEN-house-q-WEDam.mp3
Time: 26s
Title: FTC-AMGEN-house-q-WEDam
Out-cue: rare disease treatments]
TAG: Correspondent Jeremy House reporting.
——————————-
VERBATIM: The Federal Trade Commission says the deal, announced last December, would give Amgen unfair leverage to block competition for Horizon medications. The FTC said the deal would entrench Horizon’s monopoly position on treatments for thyroid eye disease and chronic refractory gout. Amgen leaders said in December that the deal would give their company a strong platform to expand into rare disease treatments.